Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNCP-β-NalA
- Development stage
- Preclinical
- Lead developer
- Medical University of Vienna
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Subcutaneous
01
Overview
DNCP-β-NalA is an experimental peptide-drug conjugate (PDC) designed as a potent agonist of the kappa opioid receptor (KOR). It is being investigated for its potential to treat severe abdominal pain associated with inflammatory bowel disease (IBD) by leveraging the analgesic and anti-inflammatory effects of KOR activation. The compound acts as a full agonist for the Gαi signaling pathway (pEC50 = 9.6 in wildtype KOR) and exhibits a specific signaling profile regarding β-arrestin recruitment. Research into DNCP-β-NalA has highlighted how specific KOR mutations (such as E209A and Y312A) can alter its efficacy and signaling bias, providing insights into the molecular pharmacology of KOR-targeted therapies for visceral pain.
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NOP (Nociceptin/orphanin FQ peptide receptor)
Beyond the preview
Go deeper on DNCP-β-NalA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNCP-β-NalA.